Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc has strengthened its executive team by appointing Dr. Michelle Morrow as Chief Scientific Officer, a seasoned leader with nearly two decades of experience in oncology therapeutics. Dr. Morrow is expected to play a critical role in advancing Avacta’s therapeutic programs, particularly leveraging the company’s pre|CISION platform and leading the clinical development of novel cancer treatments. The move underscores Avacta’s commitment to innovating in the targeted oncology drug space and improving patient outcomes.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
